AJP - Endo Ad Instruments
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Endocrinol Metab 281: E1022-E1028, 2001;
0193-1849/01 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (24)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hardin, D. S.
Right arrow Articles by Seilheimer, D. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hardin, D. S.
Right arrow Articles by Seilheimer, D. K.
Vol. 281, Issue 5, E1022-E1028, November 2001

Mechanisms of insulin resistance in cystic fibrosis

Dana S. Hardin1,2,3, Adrian Leblanc3, Gailen Marshall2, and Dan K. Seilheimer3

1 University of Texas Southwestern Medical School, Dallas 75390; 2 University of Texas Health Science Center, and 3 Baylor College of Medicine, Houston, Texas 77030

Cystic fibrosis (CF) is associated with a high incidence of diabetes. Studies evaluating causes of CF-related diabetes (CFRD) have consistently documented decreased insulin secretion. In patients with CFRD, insulin sensitivity has been documented to be decreased, but controversy exists in patients with normal or impaired glucose tolerance (IGT). We undertook this study 1) to reexplore insulin sensitivity in patients with IGT and 2) to evaluate potential mechanisms of insulin resistance in CF, including GLUT-4 translocation, elevation of serum cytokines, and free fatty acid (FFA) levels. We recruited nine CF subjects with impaired glucose tolerance (IGTCF) and nine age-, gender-, and body mass index-matched control volunteers. Each underwent a hyperinsulinemic euglycemic clamp (200 mU · m-2 · min-1) to measure insulin sensitivity. A muscle biopsy was obtained at maximal insulin stimulation for measure of GLUT-4 translocation with sucrose gradients. An oral glucose tolerance test and National Institutes of Health (NIH) clinical status scores were measured in all volunteers. We also measured tumor necrosis factor (TNF)-alpha levels and FFA in all subjects. Additionally, we report the results of TNF-alpha and FFA in 32 CF patients previously studied by our group. Results were that glucose disposal rate (GDR) was significantly lower in the CFIGT subjects than in controls, indicative of impaired insulin action. GLUT-4 translocation was impaired in CF and correlated with GDR. TNF-alpha levels were higher in all CF subjects than in controls and correlated with GDR. There was no difference in FFA between CF and control subjects. Modified NIH clinical status scores were inversely correlated with GDR and TNF-alpha levels. We conclude that IGTCF patients have decreased peripheral insulin sensitivity. Mechanisms include elevation of TNF-alpha and impaired translocation of GLUT-4.

insulin resistance; cytokines; tumor necrosis factor-alpha ; free fatty acids


This article has been cited by other articles:


Home page
 JRSMHome page
D. Peckham
Routine screening for cystic fibrosis-related diabetes
J R Soc Med, July 1, 2009; 102(Supplement_1): 36 - 39.
[Full Text] [PDF]

Home page
 J Intensive Care MedHome page
T. M. Kremer, R. G. Zwerdling, P. H. Michelson, and B. P. O'Sullivan
Intensive Care Management of the Patient With Cystic Fibrosis
J Intensive Care Med, May 1, 2008; 23(3): 159 - 177.
[Abstract] [PDF]

Home page
 Diabetes CareHome page
V. Preumont, M. P. Hermans, P. Lebecque, and M. Buysschaert
Glucose Homeostasis and Genotype-Phenotype Interplay in Cystic Fibrosis Patients With CFTR Gene {Delta}F508 Mutation
Diabetes Care, May 1, 2007; 30(5): 1187 - 1192.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
M. E Street, M. A Ziveri, C. Spaggiari, I. Viani, C. Volta, G. L. Grzincich, R. Virdis, and S. Bernasconi
Inflammation is a modulator of the insulin-like growth factor (IGF)/IGF-binding protein system inducing reduced bioactivity of IGFs in cystic fibrosis
Eur. J. Endocrinol., January 1, 2006; 154(1): 47 - 52.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
R. Amin, J. Bean, K. Burklow, and J. Jeffries
The Relationship Between Sleep Disturbance and Pulmonary Function in Stable Pediatric Cystic Fibrosis Patients
Chest, September 1, 2005; 128(3): 1357 - 1363.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
M. Rafii, K. Chapman, C. Stewart, E. Kelly, A. Hanna, D. C Wilson, E. Tullis, and P. B Pencharz
Changes in response to insulin and the effects of varying glucose tolerance on whole-body protein metabolism in patients with cystic fibrosis
Am. J. Clinical Nutrition, February 1, 2005; 81(2): 421 - 426.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
S. Tofe, J. C Moreno, L. Maiz, M. Alonso, H. Escobar, and R. Barrio
Insulin-secretion abnormalities and clinical deterioration related to impaired glucose tolerance in cystic fibrosis
Eur. J. Endocrinol., February 1, 2005; 152(2): 241 - 247.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online